Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not candidates for inhibitors of programmed cell death protein 1 (PD-1) or ...

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial In this global phase III ...

While the study reached statistical significance, a <1-month improvement is not clinically significant. With the availability of mTOR, PI3CA, and AKT inhibitors, clinical trials need to consider ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies. In a phase 3, multicenter, open-label, active-controlled trial, ...